BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.490
+0.070 (4.93%)
At close: May 8, 2026, 4:00 PM EDT
1.470
-0.020 (-1.34%)
After-hours: May 8, 2026, 4:04 PM EDT
BeyondSpring Employees
BeyondSpring had 44 employees as of December 31, 2025. The number of employees increased by 4 or 10.00% compared to the previous year.
Employees
44
Change (1Y)
4
Growth (1Y)
10.00%
Revenue / Employee
n/a
Profits / Employee
-$22,864
Market Cap
61.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 44 | 4 | 10.00% |
| Dec 31, 2024 | 40 | 4 | 11.11% |
| Dec 31, 2023 | 36 | -37 | -50.68% |
| Dec 31, 2022 | 73 | -30 | -29.13% |
| Dec 31, 2021 | 103 | 12 | 13.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
| Filana Therapeutics | 20 |
| ImageneBio | 15 |
| Cingulate | 14 |
| Instil Bio | 14 |
| Dogwood Therapeutics | 8 |
BYSI News
- 18 days ago - BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs - GlobeNewsWire
- 6 weeks ago - BeyondSpring Files 2025 Annual Report on Form 10-K - GlobeNewsWire
- 3 months ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 5 months ago - BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress - TheFly
- 5 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 5 months ago - BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TheFly
- 6 months ago - BeyondSpring reports Q3 EPS (4c) vs (5c) last year - TheFly
- 9 months ago - BeyondSpring reports Q2 EPS (10c) vs (4c) last year - TheFly